Compare THAR & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THAR | XTNT |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.8M | 82.6M |
| IPO Year | 2022 | N/A |
| Metric | THAR | XTNT |
|---|---|---|
| Price | $2.87 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 565.1K | 230.5K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $133,083,000.00 |
| Revenue This Year | N/A | $15.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $63.01 |
| Revenue Growth | N/A | ★ 16.88 |
| 52 Week Low | $0.95 | $0.34 |
| 52 Week High | $9.08 | $0.95 |
| Indicator | THAR | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 51.93 | 45.69 |
| Support Level | $2.77 | $0.68 |
| Resistance Level | $3.56 | $0.81 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 41.53 | 12.51 |
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.